AlphaTON Capital Corp. (ATON)
NASDAQ: ATON · Real-Time Price · USD
6.06
+0.17 (2.83%)
Sep 9, 2025, 12:52 PM - Market open
AlphaTON Capital Employees
As of March 31, 2025, AlphaTON Capital had 4 total employees, including 3 full-time and 1 part-time employees. The number of employees decreased by 3 or -42.86% compared to the previous year.
Employees
4
Change (1Y)
-3
Growth (1Y)
-42.86%
Revenue / Employee
n/a
Profits / Employee
-$1,691,750
Market Cap
13.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 4 | -3 | -42.86% |
| Mar 31, 2024 | 7 | 0 | - |
| Mar 31, 2023 | 7 | 1 | 16.67% |
| Mar 31, 2022 | 6 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Amazon.com | 1,546,000 |
| Berkshire Hathaway | 392,400 |
| JPMorgan Chase & Co. | 317,233 |
| Microsoft | 228,000 |
| Alphabet | 187,103 |
| Apple | 164,000 |
| Tesla | 125,665 |
| Taiwan Semiconductor Manufacturing Company | 83,825 |
ATON News
- 6 days ago - AlphaTON Capital Corp Launches TON Digital Asset Treasury Strategy for the Telegram Ecosystem - GlobeNewsWire
- 6 weeks ago - Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025 - GlobeNewsWire
- 2 months ago - Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements - GlobeNewsWire
- 3 months ago - Portage Biotech and Compedica Stock-for-Stock Exchange - GlobeNewsWire
- 4 months ago - Portage Biotech Stock Surges As It Prepares For Human Trial - Benzinga
- 4 months ago - Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 - GlobeNewsWire
- 5 months ago - Why Is Portage Biotech Stock Skyrocketing Friday? - Benzinga
- 5 months ago - Portage Biotech Shares More Than Double After Results of PORT-7 Tumor Treatment Trial - Market Watch